Rigel Expands Relationship With Kissei To include REZLIDHIA In Japan, The Republic Of Korea And Taiwan; Will Receive An Upfront Cash Payment Of $10M With The Potential For Up To $152.5M In Future Development, Regulatory, And Commercial Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
Rigel Pharmaceuticals has expanded its partnership with Kissei Pharmaceutical to include the development and commercialization of REZLIDHIA in Japan, Korea, and Taiwan. Rigel will receive a $10M upfront payment and could earn up to $152.5M in milestone payments.
September 03, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rigel Pharmaceuticals has entered into an exclusive agreement with Kissei for the development and commercialization of REZLIDHIA in Japan, Korea, and Taiwan. This deal includes a $10M upfront payment and potential milestone payments up to $152.5M.
The agreement with Kissei significantly expands Rigel's market reach for REZLIDHIA, providing immediate financial benefits and potential future revenue streams. This is likely to positively impact RIGL's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90